Show simple item record

dc.contributor.authorFerreira, Isabel
dc.contributor.authorCroca, Sara
dc.contributor.authorRaimondo, Maria Gabriella
dc.contributor.authorMatharu, Manjit
dc.contributor.authorMiller, Sarah
dc.contributor.authorGiles, Ian
dc.contributor.authorIsenberg, David
dc.contributor.authorIoannou, Yiannis
dc.contributor.authorHanly, John G.
dc.contributor.authorUrowitz, Murray B.
dc.contributor.authorAnderson, Nicole
dc.contributor.authorAranow, Cynthia
dc.contributor.authorAskanase, Anca
dc.contributor.authorBae, Sang-Cheol
dc.contributor.authorBernatsky, Sasha
dc.contributor.authorBruce, Ian N.
dc.contributor.authorBuyon, Jill
dc.contributor.authorClarke, Ann E.
dc.contributor.authorDooley, Mary Anne
dc.contributor.authorFortin, Paul R.
dc.contributor.authorGinzler, Ellen
dc.contributor.authorGladman, Dafna
dc.contributor.authorGordon, Caroline
dc.contributor.authorInanc, Murat
dc.contributor.authorJacobsen, Soren
dc.contributor.authorKalunian, Kenneth
dc.contributor.authorKamen, Diane
dc.contributor.authorKhamashta, Munther
dc.contributor.authorLim, Sam
dc.contributor.authorManzi, Susan
dc.contributor.authorMerrill, Joan
dc.contributor.authorNived, Ola
dc.contributor.authorPeschken, Christine
dc.contributor.authorPetri, Michelle
dc.contributor.authorRamsey Goldman, Rosalind
dc.contributor.authorRuiz Irastorza, Guillermo
dc.contributor.authorSanchez-Guerrero, Jorge
dc.contributor.authorSteinson, Kristjan
dc.contributor.authorSturfelt, Gunnar K.
dc.contributor.authorVan Vollenhoven, Ronald
dc.contributor.authorWallace, Daniel J.
dc.contributor.authorZoma, Asad
dc.contributor.authorRahman, Anisur
dc.date.accessioned2019-04-05T07:37:07Z
dc.date.available2019-04-05T07:37:07Z
dc.date.issued2017-12-22
dc.identifier.citationArthritis Research & Therapy 19 : (2017) // Article ID 287es_ES
dc.identifier.issn1478-6354
dc.identifier.issn1478-6362
dc.identifier.urihttp://hdl.handle.net/10810/32348
dc.description.abstractBackground: In patients with systemic lupus erythematosus (SLE) there is no serological test that will reliably distinguish neuropsychiatric (NP) events due to active SLE from those due to other causes. Previously we showed that serum levels of nitrated nucleosomes (NN) were elevated in a small number of patients with NPSLE. Here we measured serum NN in samples from a larger population of patients with SLE and NP events to see whether elevated serum NN could be a marker for NPSLE. Methods: We obtained serum samples from patients in the Systemic Lupus International Collaborative Clinics (SLICC) inception cohort. This included 216 patients with NP events and two matched controls with SLE but no NP events for each of these patients. For the NP patients we tested samples taken before, during and after the NP event. Results: Twenty-six patients had events attributed to SLE according to the most stringent SLICC attribution rule. In these patients there was no association between onset of event and elevated serum NN. In 190 patients in whom events were not attributed to SLE by the SLICC rules, median serum NN was elevated at the onset of event (P = 0.006). The predominant clinical features in this group of 190 patients were headache, mood disorders and anxiety. Conclusions: Serum NN levels rise at the time of an NP event in a proportion of patients with SLE. Further studies are needed to determine the value of serum NN as a biomarker for NPSLE.es_ES
dc.description.sponsorshipThis work was funded by LUPUS UK, The Rosetrees Trust and Arthritis Research UK Programme Grant 19423, and was supported by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. Drs Ioannou and Isenberg are also supported by Arthritis Research UK Grant 20164. Dr. Hanly's work was supported by the Canadian Institutes of Health Research (research grant MOP-86526). Dr. Sang-Cheol Bae's work was in part by unrestricted grant (Hanyang University 201600000001387). Dr. Caroline Gordon's work was supported by Lupus UK, Sandwell and West Birmingham Hospitals National Health Service (NHS) Trust and the NIHR/Wellcome Trust Clinical Research Facility in Birmingham. Dr Petri and the Hopkins Lupus Cohort are supported by the National Institutes of Health (NIH) (grant AR43727). The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. Dr. Clarke holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. Dr. Paul R. Fortin presently holds a tier 1 Canada Research Chair on Systemic Autoimmune Rheumatic Diseases at Universite Laval, and part of this work was done while he was still holding a Distinguished Senior Investigator of The Arthritis Society. Dr. Bruce is an NIHR Senior Investigator and is funded by Arthritis Research UK, the National Institute for Health Research Manchester Biomedical Research Unit and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Dr. Soren Jacobsen is supported by the Danish Rheumatism Association (A1028) and the Novo Nordisk Foundation (A05990). Dr. Ramsey-Goldman's work was supported by the NIH (grants 1U54TR001353 formerly 8UL1TR000150 and UL-1RR-025741, K24-AR-02318, and P60AR064464 formerly P60-AR-48098). Dr. Mary Anne Dooley's work was supported by the NIH grant RR00046. Dr. Ruiz-Irastorza is supported by the Department of Education, Universities and Research of the Basque Government. None of these funding bodies played any role in the design of the study, collection, analysis or interpretation of the data.es_ES
dc.language.isoenges_ES
dc.publisherBiomed Centrales_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectsystemic lupus erythematosuses_ES
dc.subjectneuropsychiatrices_ES
dc.subjectnucleosomeses_ES
dc.subjectnitrationes_ES
dc.subjectinternational inception cohortes_ES
dc.subjectnitric-oxide synthasees_ES
dc.subjectdisease-activityes_ES
dc.subjectheadachees_ES
dc.subjectserumes_ES
dc.subjectmetaanalysises_ES
dc.subjectbiomarkerses_ES
dc.subjectantibodieses_ES
dc.subjectdiagnosises_ES
dc.subjectplasmaes_ES
dc.titleNitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.es_ES
dc.relation.publisherversionhttps://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1495-6es_ES
dc.identifier.doi10.1186/s13075-017-1495-6
dc.departamentoesMedicinaes_ES
dc.departamentoeuMedikuntzaes_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record